Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Part B Drugs Prior Auth Policy Upd…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBluecross IdahoPolicy MP 5.01.610

    Medicare Advantage Part B Medical Drugs Step Therapy

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.610 alerts

    Get alerted when Policy MP 5.01.610 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines preferred and non-preferred Part B medical drugs for Blue Cross of Idaho Medicare Advantage members and the step-therapy criteria that govern coverage and prior authorization decisions for these drugs.

    Policy Summary
    PayerBluecross Idaho
    PolicyMedicare Advantage Part B Medical Drugs Step Therapy
    Policy CodePolicy MP 5.01.610
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewJun 26, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain prior authorization when requesting non-preferred Part B therapies and document prior use or contraindications to preferred products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    04/01/2026policy effective date shown
    Medicare Advantagelines of business
    outpatientsettings requiring preservice authorization
    365lookback period (continuation)
    20+distinct J/Q/HCPCS codes

    Coverage Criteria

    Preferred product coverage

    Preferred products within each drug class are covered when ALL of the following are met:

    Preferred product requirement: Requested drug is a preferred product listed for the drug class (see code lists).

    Preferred products enumerated by class (e.g., Avastin/Zirabev for bevacizumab; Rituxan/Ruxience for rituximab; Treprostinil NDCs listed) are primary covered agents.

    Indication requirement: Use is for an FDA‑approved indication or an indication supported by CMS‑approved compendia (Medicare Benefit Policy Manual, Chapter 15).

    Clinical appropriateness follows FDA and CMS compendia guidance.

    Failure/exemption clause: Only preferred products are considered medically necessary unless the member has a documented contraindication, intolerance, or adverse response to all preferred products in the drug class, has used all preferred products with minimal clinical response, or has been on the requested therapy within the last 365 days (continuation of prior therapy).
    Policy Summary
    PayerBluecross Idaho
    PolicyMedicare Advantage Part B Medical Drugs Step Therapy
    Policy CodePolicy MP 5.01.610
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewJun 26, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain prior authorization when requesting non-preferred Part B therapies and document prior use or contraindications to preferred products.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Codes AppendixProvider Actions, Prior Authorization, and Billing GuidanceStep Therapy RequirementsContinuation of Prior TherapyInitial Therapy CriteriaQuantity LimitsSite of CareBiosimilar Listings and HandlingBackgroundDefinitionsRevision History
    365 days (look‑back for continuation)

    Continuation exception described across class sections.

    Non-Preferred Product Exceptions

    Non-preferred products may be covered when ANY of the following are satisfied:

    Exceptions to preferred-product requirement: A) History of use of ALL preferred products resulting in minimal clinical response or residual disease activity; OR B) History of contraindication, intolerance, or adverse event(s) to ALL preferred products; OR C) Preferred product does not have an FDA‑approved indication for the requested use; OR D) Continuation of prior therapy within the past 365 days.365 days for continuation

    These constitute the explicit step‑therapy/exception criteria for non‑preferred coverage under the policy.

    Non-preferred product coverage (step therapy)

    Non-preferred products may be covered when any of the following are satisfied:

    Step‑therapy coverage conditions: (1) Member has history of use of ALL preferred products with minimal clinical response or persistent disease activity; OR (2) Member has documented contraindication, intolerance, or adverse event(s) to ALL preferred products; OR (3) The preferred product lacks an FDA‑approved indication for the requested use; OR (4) Continuation of prior therapy — member has an active/paid claim for the drug/product within the past 365 days (defines current therapy).365 days for continuation

    Prior authorization required for non‑preferred therapies; failure to secure PA may result in claim denial.

    Related Policies: None. The policy header explicitly lists no additional Blue Cross of Idaho payer policies referenced in this COVERAGE CRITERIA section; administrators should treat this document as the primary plan mapping for the listed Part B medical drugs and code-based determinations.

    Scope: This policy applies only to Medicare Advantage plans. All other lines of business are excluded; use plan-specific benefit guidance for non-Medicare Advantage members.

    Some reference products in the code listings are annotated as “excludes biosimilar” (for example, infliximab/Remicade and certain trastuzumab listings). These annotations indicate coding and coverage distinctions between the originator/reference biologic and biosimilar products and may affect adjudication and prior authorization.

    The listings include repeated annotations such as “excludes biosimilar” for some originator products (notably infliximab/Remicade). Where present, this signals the payer treats the originator and its biosimilars as separate entries for coverage and coding purposes.

    Certain products are explicitly noted as “excludes biosimilar” in the code appendix. Providers should expect special handling or distinguishing coverage rules when the originator is marked this way versus the listed biosimilar Q-codes.

    Some originator biologics appear in the codes section with the phrase “excludes biosimilar” (for example, branded infliximab/Remicade). This reflects product-level coverage distinctions that may require selecting the correct HCPCS or Q-code to match the intended product and formulary status.

    Listings in the coding appendix show originator products annotated with “excludes biosimilar” or explicitly labeled as non-preferred. These entries affect coverage handling because they separate the originator from biosimilar entries for adjudication and prior authorization.

    Infliximab entries are repeatedly described with “excludes biosimilar” in multiple code list lines, indicating that branded Remicade (infliximab) may be treated differently from infliximab biosimilars for coverage classification and prior authorization decisions.

    Certain product codes and National Drug Codes are designated Non-Preferred in the listing (examples include NDCs such as 66302-0101-01, 66302-0102-01, 66302-0105-01, 66302-0110-01). These Non-Preferred identifiers may trigger step-therapy requirements or different adjudication rules.

    The infliximab code entries repeatedly include the phrase “excludes biosimilar” for some listings (e.g., branded infliximab/Remicade), reinforcing that certain infliximab lines are separated from biosimilar entries and may be subject to distinct coverage or formulary treatment.

    Coding and Codes Appendix

    Specified NDCsNDC
    00781-3420-80National Drug Code listed for Treprostinil
    00781-3425-80National Drug Code listed for Treprostinil
    00781-3427-80National Drug Code listed for Treprostinil
    00781-3430-80National Drug Code listed for Treprostinil
    Antiangiogenic agents / Botulinum toxins (HCPCS)HCPCS
    J9035Injection, bevacizumab, 10 mg
    Q5107Injection, bevacizumab-awwb, biosimilar (Mvasi), 10 mg
    Q5118Injection, bevacizumab-awwb, biosimilar, 10 mg
    Q5126Injection, bevacizumab-bvzr, biosimilar (Zirabev), 10 mg
    Q5129Injection, bevacizumab-adcd (Vegzelma), biosimilar, 10 mg
    Q5160Injection, bevacizumab-nwgd (Jobevne), biosimilar 10 mg
    J0585Injection, onabotulinumtoxinA, 1 unit (Botox)
    J0586Injection, abobotulinumtoxinA, 5 units (Dysport)
    Botulinum toxins / Complement inhibitors / Denosumab (HCPCS)HCPCS
    J0587Injection, rimabotulinumtoxinB, 100 units (Myobloc)
    J0588Injection, incobotulinumtoxinA, 1 unit (Xeomin)
    J0589Injection, daxibotulinumtoxina-lanm, 1 unit (Daxxify)
    J1299Injection, eculizumab, 2 mg
    J1303Injection, ravulizumab-cwvz, 10 mg
    Q5151Injection, eculizumab-aagh (Epysqli), biosimilar, 2 mg
    Q5152Injection, eculizumab-aeeb (Bkemv), biosimilar, 2 mg
    J0897Injection, denosumab, 1 mg
    Q5136Injection, denosumab-bbdz (Jubbonti/Wyost), biosimilar, 1 mg
    Q5157Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
    Antiangiogenic agents (bevacizumab and biosimilars)HCPCS
    J9035Injection, bevacizumab, 10 mg
    Q5107Injection, bevacizumab-awwb (Mvasi), 10 mg
    Q5118Injection, bevacizumab-awwb, 10 mg
    Q5126Injection, bevacizumab-maly (Alymsys), 10 mg
    Q5129Injection, bevacizumab-adcd (Vegzelma), 10 mg
    Q5160Injection, bevacizumab-nwgd (Jobevne), 10 mg
    Botulinum toxinsHCPCS
    J0585Injection, onabotulinumtoxinA, 1 unit (Botox)
    J0586Injection, abobotulinumtoxinA, 5 units (Dysport)
    J0587Injection, rimabotulinumtoxinB, 100 units (Myobloc)
    J0588Injection, incobotulinumtoxinA, 1 unit (Xeomin)
    J0589Injection, daxibotulinumtoxina-lanm, 1 unit (Daxxify)
    Complement inhibitorsHCPCS
    J1299Injection, eculizumab, 2 mg
    J1303Injection, ravulizumab-cwvz, 10 mg
    Q5151Injection, eculizumab-aagh (Epysqli), biosimilar, 2 mg
    Q5152Injection, eculizumab-aeeb (Bkemv), biosimilar, 2 mg
    Denosumab (osteoporosis/bone)HCPCS
    J0897Injection, denosumab, 1 mg
    Q5136Injection, denosumab (biosimilar group), 1 mg
    Q5157Injection, denosumab-bbdz (Jubbonti/Wyost), biosimilar, 1 mg
    Q5158Injection, denosumab-bmwo, biosimilar, 1 mg
    Q5159Injection, denosumab-bnht, biosimilar, 1 mg
    Q5161Injection, denosumab-dssb, biosimilar, 1 mg
    Q5162Injection, denosumab-nxxp, biosimilar, 1 mg
    Monoclonal antibodies - rituximab groupHCPCS
    J9311Injection, rituximab 10 mg and hyaluronidase
    J9312Injection, rituximab, 10 mg
    Q5115Injection, rituximab-abbs (Truxima), biosimilar, 10 mg
    Q5119Injection, rituximab-pvvr (Ruxience), biosimilar, 10 mg
    Q5123Injection, rituximab-arrx (Riabni), biosimilar, 10 mg
    Viscosupplementation (hyaluronic acid)HCPCSCovered
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
    J7321Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose
    J7322Hyaluronan or derivative, Hymovis or Hymovis One, for intra-articular injection
    Growth factors and pulmonary vasodilator (pegfilgrastim, eflapegrastim, treprostinil)HCPCS
    J2506Injection, eflapegrastim-xnst, 0.1 mg
    Q5108Injection, pegfilgrastim (various products), 0.5 mg
    Q5111Injection, pegfilgrastim-jmdb (Fulphila)
    Q5120Injection, pegfilgrastim-cbqv (Udenyca)
    Q5122Injection, pegfilgrastim-bmez (ZIEXTENZO)
    Q5127Injection, pegfilgrastim-apgf (Nyvepria)
    Q5130Injection, pegfilgrastim-fpgk (Stimufend)
    J3285Injection, treprostinil, 1 mg
    TNF-alpha inhibitors - infliximab groupHCPCS
    J1745Injection, infliximab
    Q5103Injection, infliximab-dyyb (Inflectra), biosimilar, 10 mg
    Q5104Injection, infliximab-abda (Renflexis), biosimilar, 10 mg
    Q5121Injection, infliximab-axxq (AVSOLA), biosimilar, 10 mg
    Trastuzumab and biosimilarsmixed
    trastuzumab (various)Injection, trastuzumab and multiple biosimilars, 10 mg (codes listed in text)
    Treprostinil NDC listNDC
    NDCs (treprostinil)Multiple NDCs enumerated for treprostinil and Remodulin formulations (e.g., 00781-3420-80, 00781-3425-80, 00703-0666-01, 42023-0206-01, etc.)
    Listed injectable J-codes and hyaluronansHCPCS
    J3285Injection, treprostinil, 1 mg (treprostinil)
    J1745Injection, infliximab, 10 mg (infliximab)
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
    J7321Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, injection, per dose
    J7322Hyaluronan or derivative, Hymovis or Hymovis One, for intra-articular injection, 1 mg
    J7323Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
    J2506Injection, eflapegrastim-xnst, 0.1 mg / pegfilgrastim listings
    Q-codes for infliximab and pegfilgrastim biosimilarsHCPCS
    Q5103Injection, infliximab-dyyb (Inflectra), biosimilar, 10 mg
    Q5104Injection, infliximab-abda (Renflexis), biosimilar, 10 mg
    Q5121Injection, infliximab-axxq (AVSOLA), biosimilar, 10 mg
    Q5111Injection, pegfilgrastim-jmdb (Fulphila) / other Q-codes for pegfilgrastim biosimilars
    Q5120Injection, pegfilgrastim-cbqv (Udenyca)
    Q5122Injection, pegfilgrastim-bmez (ZIEXTENZO)
    Q5127Injection, pegfilgrastim-apgf (Nyvepria)
    Q5130Injection, pegfilgrastim-fpgk (Stimufend)
    Q5130Injection, pegfilgrastim-pbbk (Fylnetra) (appears referenced)
    Treprostinil NDC groupsNDC
    NDC: 00781-3420-80Treprostinil NDC listed as Preferred
    NDC: 00781-3425-80Treprostinil NDC listed as Preferred
    NDC: 00781-3427-80Treprostinil NDC listed as Preferred
    NDC: 00781-3430-80Treprostinil NDC listed as Preferred
    NDC: 00703-0666-01Treprostinil NDC (listed among groups, Preferred/Non-Preferred grouping present)
    Viscosupplementation and other injectable HCPCSHCPCS
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular
    J7321Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, injection, per dose
    J7322Hyaluronan or derivative, Hymovis or Hymovis One, injection, per dose
    J7323Hyaluronan or derivative, injection, 1 mg (Euflexxa referenced)
    J9355Code referenced in drug list (appearance in document)
    Pegfilgrastim biosimilars (Q-codes)HCPCS
    Q5108Injection, pegfilgrastim (group reference)
    Q5111Injection, pegfilgrastim-jmdb (Fulphila) / related Q-code group
    Q5120Injection, pegfilgrastim-cbqv (Udenyca) / related
    Q5122Injection, pegfilgrastim-bmez (ZIEXTENZO)
    Q5127Injection, pegfilgrastim-apgf (Nyvepria)
    Q5130Injection, pegfilgrastim-fpgk (Stimufend) / pegfilgrastim-pbbk (Fylnetra)
    Treprostinil HCPCSHCPCS
    J3285Injection, treprostinil, 1 mg
    Infliximab and biosimilarsHCPCS
    J1745Injection, infliximab
    Q5103Injection, infliximab-dyyb (Inflectra), 10 mg
    Q5104Injection, infliximab-abda (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq (AVSOLA), 10 mg
    Trastuzumab biosimilars (text list)mixed
    trastuzumab (various J-codes implied)Trastuzumab and multiple biosimilars listed (10 mg presentations referenced)
    Treprostinil NDC groups (Preferred and Non-Preferred)NDC
    NDC groupsTreprostinil National Drug Codes groups e.g., 00781-3420-80, 00781-3425-80, 00781-3427-80, 00781-3430-80 and multiple 00703-... and 42023-... and 43598-... and 66302-... series
    Covered HCPCS/CPT/QJ codes (listed section fragment)mixed
    J3285Injection, treprostinil, 1 mg (treprostinil)
    J1745Injection, infliximab
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular injection
    J7321Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, injection, per dose
    Biosimilar HCPCS/Q-codesHCPCS
    Q5103Injection, infliximab-dyyb (Inflectra), 10 mg
    Q5104Injection, infliximab-abda (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq (AVSOLA), 10 mg
    Pegfilgrastim biosimilar Q-codesHCPCS
    Q5111Injection, pegfilgrastim-cbqv
    Q5122Injection, pegfilgrastim-bmez
    Q5127Injection, pegfilgrastim-apgf (Nyvepria)
    Q5130Injection, pegfilgrastim-fpgk (Stimufend)
    National Drug Codes (NDCs) for treprostinil and related productsNDC
    NDC: 00781-3420-80Treprostinil preferred NDC listing (partial)
    NDC: 00781-3425-80Treprostinil preferred NDC listing (partial)
    NDC: 00781-3427-80Treprostinil preferred NDC listing (partial)
    NDC: 00781-3430-80Treprostinil preferred NDC listing (partial)
    NDC: 00703-0666-01Treprostinil / Remodulin NDC (listed)
    NDC: 42023-0206-01Treprostinil NDC (listed)
    NDC: 43598-0646-11Treprostinil NDC (listed)
    NDC: 66302-0101-01Non-preferred product NDC (listed)
    Viscosupplementation / Hyaluronan J-codesHCPCS
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular injection
    J7321Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, injection, per dose
    J7322Hyaluronan or derivative, Hymovis or Hymovis One, for intra-articular
    J7324Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
    J7325Hyaluronan or derivative injection, 1 mg
    TreprostinilHCPCSCovered
    J3285Injection, treprostinil, 1 mg (treprostinil)
    Infliximab and biosimilarsmixed
    J1745Injection, infliximab
    Q5103Injection, infliximab-dyyb, biosimilar (Inflectra), 10 mg
    Q5104Injection, infliximab-abda, biosimilar (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq, biosimilar (AVSOLA), 10 mg
    Pegfilgrastim / G-CSF agents and biosimilarsmixed
    J2506Injection, eflapegrastim-xnst, 0.1 mg
    Q5108Injection, pegfilgrastim (general code referenced)
    Q5111Injection, pegfilgrastim-jmdb (Fulphila) or associated pegfilgrastim biosimilars
    Q5120Injection, pegfilgrastim-cbqv (Udenyca)
    Q5122Injection, pegfilgrastim-bmez (ZIEXTENZO)
    Q5127Injection, pegfilgrastim-apgf (Nyvepria)
    Q5130Injection, pegfilgrastim-fpgk (Stimufend)
    Other J-codes referencedHCPCS
    J9355Listed in document (context suggests an oncology/supportive care HCPCS)
    J9356Listed in document (context suggests an oncology/supportive care HCPCS)
    Pegfilgrastim and treprostinil HCPCS/Q and J codesHCPCS
    Q5127Injection, pegfilgrastim-apgf (Nyvepria)
    Q5130Injection, pegfilgrastim-fpgk (Stimufend) / pegfilgrastim-pbbk (Fylnetra)
    Q5111Injection, pegfilgrastim-pbbk
    Q5120Injection, pegfilgrastim-cbqv (Udenyca)
    Q5122Injection, pegfilgrastim-bmez (ZIEXTENZO)
    J3285Injection, treprostinil, 1 mg (treprostinil)
    Treprostinil J-code with NDC pack referencesHCPCS | NDC
    J3285Injection, treprostinil, 1 mg (treprostinil); multiple NDC pack codes referenced
    Infliximab and biosimilarsHCPCS
    J1745Injection, infliximab
    Q5103Injection, infliximab-dyyb (Inflectra), 10 mg
    Q5104Injection, infliximab-abda (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq (AVSOLA), 10 mg
    Intra-articular hyaluronan HCPCS J-codesHCPCS
    J7325Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
    J7321Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, injection, per dose
    Additional hyaluronan codesHCPCS
    J7326Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
    Repeated hyaluronan referenceHCPCS
    J7325Also referenced multiple times in hyaluronan grouping
    Other J-codes referencedHCPCS
    J9355Referenced (context fragment)
    J9356Referenced (context fragment)
    J1449Referenced (context fragment)
    J2506Injection, pegfilgrastim (general listing)
    Infliximab and biosimilarsHCPCS
    Q5103Injection, infliximab-dyyb, biosimilar (Inflectra), 10 mg
    Q5104Injection, infliximab-abda, biosimilar (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq, biosimilar (AVSOLA), 10 mg
    J1745Injection, infliximab
    Viscosupplementation (hyaluronic acid)HCPCS
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular injection, per dose
    J7321Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose
    J7325Hyaluronan or derivative, Synvisc or Synvisc-One, for injection, 1 mg
    J7326Hyaluronan or derivative, Gel-One, for intra-articular injection
    Other oncology/supportive care J-codesHCPCS
    J9355Listed (appears in sequence in document)
    J9356Listed (appears in sequence in document)
    Pegfilgrastim and biosimilarsHCPCS
    J2506Injection, pegfilgrastim
    Q5108Injection, pegfilgrastim-jmdb (Fulphila) or related pegfilgrastim codes
    Q5111Injection, pegfilgrastim-cbqv (Udenyca)
    Q5120Injection, pegfilgrastim-bmez (ZIEXTENZO)
    Q5122Injection, pegfilgrastim-apgf (Nyvepria)
    Q5127Injection, pegfilgrastim-fpgk (Stimufend)
    Q5130Injection, pegfilgrastim-pbbk (Fylnetra)
    Treprostinil (Remodulin)HCPCSCovered
    J3285Injection, treprostinil, 1 mg (treprostinil)
    Additional Q-codes referencedHCPCS
    Q5112Listed pegfilgrastim-related Q-code sequence
    Q5113Listed pegfilgrastim-related Q-code sequence
    Q5114Listed pegfilgrastim-related Q-code sequence
    Q5116Listed pegfilgrastim-related Q-code sequence
    Q5117Listed pegfilgrastim-related Q-code sequence
    Q5146Listed (appears in sequence)
    National Drug Codes (selected treprostinil/Remodulin examples)NDC
    NDC: 00781-3420-80Treprostinil National Drug Code (listed as Preferred)
    NDC: 00781-3425-80Treprostinil National Drug Code (listed as Preferred)
    NDC: 00781-3427-80Treprostinil National Drug Code (listed as Preferred)
    NDC: 00781-3430-80Treprostinil National Drug Code (listed as Preferred)
    NDC: 00703-0666-01Remodulin National Drug Code (listed)
    NDC: 00703-0676-01Remodulin National Drug Code (listed)
    NDC: 42023-0206-01Remodulin National Drug Code (listed)
    Non-preferred product codes (examples)NDCNot Covered
    66302-0101-01Listed non-preferred NDC/code
    66302-0102-01Listed non-preferred NDC/code
    66302-0105-01Listed non-preferred NDC/code
    66302-0110-01Listed non-preferred NDC/code
    Mixed listing reiterationHCPCS
    Q5121Injection, infliximab-axxq (AVSOLA), 10 mg
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    Pegfilgrastim and related growth factor codesHCPCS|Q-code|J-code|mixed
    Q5122Injection, pegfilgrastim-bmez (ZIEXTENZO)
    Q5120Injection, pegfilgrastim-cbqv
    Q5111Injection, pegfilgrastim-jmdb
    Q5127Injection, pegfilgrastim-apgf (Nyvepria)
    Q5130Injection, pegfilgrastim-fpgk (Stimufend)
    J3285Injection, treprostinil, 1 mg (treprostinil)
    J2506Injection, eflapegrastim-xnst, 0.1 mg
    Q5108Injection, pegfilgrastim (general pegfilgrastim code referenced)
    Infliximab / TNF-alpha inhibitor codesHCPCS|Q-code|J-code|mixed
    Q5103Injection, infliximab-dyyb (Inflectra), 10 mg
    Q5104Injection, infliximab-abda (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq (AVSOLA), 10 mg
    J1745Injection, infliximab
    Viscosupplementation (hyaluronic acid) codesJ-code|HCPCS
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular injection
    J7321Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, injection, per dose
    J7322Hyaluronan or derivative, Hymovis or Hymovis One, for intra-articular
    J7325Hyaluronan or derivative, Synvisc or Synvisc-One
    J7326Hyaluronan or derivative, Gel-One
    J7327Monovisc (viscosupplementation) per dose
    J7328GELSYN-3
    J7329Trivisc
    J7331SYNOJOYNT
    1–10 of 11
    1/2
    Other J-codes referencedJ-code
    J1449Hyaluronan / other injectables referenced (code listed in sequence)
    J2506Injection, eflapegrastim-xnst, 0.1 mg
    Treprostinil codes (preferred/non-preferred NDC groups listed)J-code
    J3285Injection, treprostinil, 1 mg (treprostinil) (repeated)
    Additional pegfilgrastim Q-codesQ-code
    Q5111Injection, pegfilgrastim-jmdb
    Q5120Injection, pegfilgrastim-cbqv
    Q5130Injection, pegfilgrastim-pbbk
    Unit strength — treprostinil
    Unit strength (treprostinil)Treprostinil unit strength: 1 mg
    Dose unit mapping1 mg (treprostinil) per J3285
    Treprostinil preferred NDCsNDCs 00781-3420-80; 00781-3425-80; 00781-3427-80; 00781-3430-80 listed as Preferred
    Dose unit — 1 mg (treprostinil) per J3285
    Dose unit (treprostinil) per J-code1 mg (treprostinil) administered per J3285
    Treprostinil J-codeJ3285 — Injection, treprostinil, 1 mg
    Pegfilgrastim/eflapegrastim cross-referenceJ2506 — eflapegrastim 0.1 mg; pegfilgrastim biosimilars listed at 0.5 mg
    Dose concentration listed — pegfilgrastim / eflapegrastim
    Pegfilgrastim dose concentrationPegfilgrastim dosing concentration listed as 0.5 mg
    Eflapegrastim dose concentrationEflapegrastim dosing concentration listed as 0.1 mg
    Related HCPCSJ2506 referenced for eflapegrastim/pegfilgrastim listings
    Dosage unit — common dosing references (10 mg example omitted here)
    Pegfilgrastim dosing unitPegfilgrastim dosing unit: 0.5 mg (listed for pegfilgrastim and biosimilars)
    Pegfilgrastim biosimilar Q-codesMultiple Q-codes listed for pegfilgrastim biosimilars (e.g., Q5111, Q5120, Q5122, Q5127, Q5130)
    Eflapegrastim referenceEflapegrastim-xnst listed at 0.1 mg (J2506) alongside pegfilgrastim entries
    Pegfilgrastim dosing unit — 0.5 mg listing
    Pegfilgrastim dosing unit (reiterate)0.5 mg dosing unit listed for pegfilgrastim and its biosimilars
    HCPCS/Q-code examplesQ5111 (Fulphila), Q5120 (Udenyca), Q5122 (ZIEXTENZO) cited in dosing section
    Eflapegrastim concentrationEflapegrastim listed at 0.1 mg (J2506)
    Policy effective / coding effective date — 04/01/2026
    Policy / coding effective datePolicy and coding effective date: 04/01/2026
    Coding updates notedQ5161 and Q5162 added as new non-preferred denosumab products effective 4/1/26
    Treprostinil NDCs noted in effective-period coding listTreprostinil NDCs (e.g., 00781-3420-80 etc.) appear in the coding appendix effective 4/1/26

    Provider Actions, Prior Authorization, and Billing Guidance

    Prior Authorization

    Use preferred products first; exceptions allow non‑preferred

    Preferred products listed for each drug class are considered medically necessary when prescribed for FDA‑approved indications or uses accepted in CMS‑approved compendia; only preferred products are considered medically necessary unless the member has a documented contraindication/intolerance/adverse response to all preferred products, has used all preferred products with minimal clinical response, or has been on the requested therapy within the last 365 days.

    Prior Authorization

    Prior authorization required for non‑preferred therapies; step therapy applies in listed settings

    Prior authorization is required for non‑preferred medical‑benefit therapies under Blue Cross of Idaho Medicare Advantage, and step therapy will be required when medications are administered under the member's medical benefit in outpatient/infusion/home settings; coverage of a non‑preferred product requires meeting a step‑therapy exception.

    • Step therapy applies in: clinician/physician office; home health; home infusion; outpatient hospital and dialysis; surgical day care.
    • If a non‑preferred therapy is given without prior authorization, the claim may be denied.
    Prior Authorization

    PA decisions tied to listed HCPCS / Q‑codes for bevacizumab/biosimilars

    Prior authorization and coverage determinations will reference the HCPCS J‑ and HCPCS Q‑codes shown in the codes appendix to identify bevacizumab and its biosimilars (e.g., J9035 and adjacent Q‑codes) when adjudicating claims.

    • Examples: J9035 (bevacizumab) and Q5107/Q5118/Q5126/Q5129/Q5160 for bevacizumab biosimilars.
    Prior Authorization

    PA applies to listed injectable specialty drugs and their J‑codes

    Prior authorization applies to the injectable specialty drugs listed by J‑codes and associated entries in the coding appendix; examples include treprostinil (J3285), infliximab (J1745) and hyaluronan viscosupplementation J‑codes.

    • Treprostinil: J3285 (Injection, treprostinil, 1 mg).
    • Infliximab: J1745.
    • Hyaluronans: J7318, J7320–J7323, etc.
    Billing Rule

    Reference specific HCPCS/J and Q‑codes for PA and billing

    Use the enumerated HCPCS/J and Q‑codes in the codes section when requesting authorization or submitting claims for viscosupplements and injectable biologics—these exact codes are used for billing and authorization lookups.

    • Viscosupplementation examples: J7318, J7320, J7321, J7322, J7323.
    • Biologic examples: J9355, J1745, J3285.
    Prior Authorization

    PA and coverage depend on the exact HCPCS/Q/NDC mappings

    Prior authorization requirements and coverage status are influenced by the specific HCPCS/Q‑codes and NDCs enumerated in the appendix; the document maps codes (e.g., J3285, J1745 and multiple Q‑codes) to preferred/non‑preferred listings.

    • Treprostinil mapping: J3285 plus multiple preferred and non‑preferred NDCs.
    • Infliximab mapping: J1745 and biosimilar Q‑codes (Q5103/Q5104/Q5121).
    Prior Authorization

    PA covers listed J‑ and Q‑coded injectable products (e.g., hyaluronans, treprostinil)

    Prior authorization applies to many injectable products identified by J‑ and Q‑codes in the coding appendix; hyaluronan viscosupplements and treprostinil are among the products listed with J‑codes that should be used for authorization requests.

    • Hyaluronans: J7318, J7320–J7325.
    • Treprostinil: J3285 and listed NDCs.
    Documentation Required

    Submit matching HCPCS/Q/J codes with PA requests

    When requesting prior authorization for specialty injectables, submit the correct HCPCS/Q/J code and supporting documentation that corresponds to the administered product as listed in the codes appendix; authorizations are code‑driven.

    • Examples of codes to include: J3285 (treprostinil), J1745 (infliximab) and applicable Q‑codes for biosimilars.
    • Providers must match the claim/authorization code to the specific product/NDC submitted.
    Billing Rule

    Codes map to coverage categories — use the exact code shown

    HCPCS/Q‑codes listed for infliximab, hyaluronan viscosupplements, trastuzumab and treprostinil are used to classify coverage (preferred, non‑preferred, biosimilar); ensure the code submitted matches the payer's listed classification to avoid processing issues.

    • Infliximab codes: J1745 and biosimilar Q‑codes (Q5103, Q5104, Q5121).
    • Hyaluronan codes: J7318, J7320, J7321, J7325, J7326.
    Billing Rule

    New non‑preferred denosumab Q‑codes effective 04/01/2026

    Coding updates effective 04/01/2026 added Q5161 and Q5162 as new non‑preferred denosumab product codes; use these codes per the updated code list when seeking authorization or submitting claims.

    • Q5161 and Q5162 added as non‑preferred denosumab codes effective 04/01/2026.
    Step Therapy

    Step therapy exceptions that allow non‑preferred coverage

    Coverage of non‑preferred products requires meeting one of the explicit exceptions: trial and minimal response to ALL preferred products, contraindication/intolerance/adverse events to ALL preferred products, lack of FDA‑approved indication for preferred product, or continuation of prior therapy within the past 365 days.

    • History of use of ALL preferred products with minimal clinical response.
    • Documented contraindication/intolerance/adverse events to ALL preferred products.
    • Preferred product lacks FDA indication for the requested use.
    • Continuation of prior therapy within the last 365 days.
    Documentation Required

    Documentation required to satisfy non‑preferred step therapy criteria

    To obtain coverage for a non‑preferred product, document one of the allowed step‑therapy criteria (failure of all preferred agents, contraindication/intolerance to all preferred agents, preferred product lacks FDA indication, or member continuation within 365 days).

    • Demonstrate history of use of ALL preferred products with minimal response.
    • Provide documentation of contraindication/intolerance/adverse events to ALL preferred products.
    • Show FDA indication gap for preferred product or evidence of prior use within 365 days.
    Note

    Preference status may change PA and coverage decisions

    Preferred versus non‑preferred designations are shown for some agents (for example treprostinil and certain NDC groups); these preference labels may affect prior authorization and utilization management decisions.

    • Treprostinil NDC groupings are labeled Preferred or Non‑Preferred in the codes appendix.
    • Expect utilization controls when NDCs are designated Non‑Preferred.
    Note

    Biosimilar vs originator listings may imply step/substitution expectations

    Biosimilar listings alongside originator products suggest the plan may favor specific biosimilars or apply product‑preference rules that can imply step or substitution expectations.

    • Examples: infliximab biosimilars (Inflectra Q5103, Renflexis Q5104, AVSOLA Q5121) are listed separately from branded infliximab entries.
    • Pegfilgrastim biosimilars and originator are enumerated with Q‑codes and some lines note 'excludes biosimilar'.
    Note

    Treprostinil NDC groupings indicate potential preference/step edits

    Preferred vs Non‑Preferred NDC groupings for treprostinil are explicitly differentiated in the code lists, implying plan‑level preference or step edits may control dispensing and coverage.

    • Preferred treprostinil NDCs: e.g., 00781‑3420‑80, 00781‑3425‑80, 00781‑3427‑80, 00781‑3430‑80.
    • Non‑Preferred examples include NDCs in the 66302‑xxxx series (66302‑0101‑01, 66302‑0102‑01, 66302‑0105‑01, 66302‑0110‑01).
    Note

    Originator vs biosimilar coding is tracked separately

    The code lists separate originator biologics from biosimilars (for example branded infliximab versus its biosimilars), which reflects that the payer may track and manage biosimilars and reference products separately when authorizing or adjudicating claims.

    • Infliximab originator entries include 'excludes biosimilar' language while biosimilars have distinct Q‑codes (Q5103/Q5104/Q5121).
    Note

    Preferred designations guide product selection for coverage

    Preferred versus non‑preferred designations are indicated in multiple drug listings (e.g., treprostinil and infliximab) and may be used to determine which product should be tried first for coverage to be approved.

    • Providers should select preferred NDCs/HCPCS when possible to minimize need for exceptions.
    • Non‑preferred designations require documented exception criteria for coverage.
    Note

    Follow preferred/non‑preferred annotations in the code appendix

    Some product entries are explicitly marked Preferred or Non‑Preferred in the codes appendix; providers should use the listed preferred product when clinically appropriate or document an allowed exception to request non‑preferred coverage.

    • Example: branded versus biosimilar infliximab listings show differing annotations that can affect coverage.
    Note

    Payer tracks biosimilars and originators separately

    Both biosimilar and originator products are listed with distinct HCPCS and Q‑codes; the payer may monitor and manage these separately for authorization and claims processing.

    • Examples: infliximab and its biosimilars (Q5103/Q5104/Q5121) are enumerated alongside J1745.
    Note

    Policy applies to Medicare Advantage Part B step therapy program

    The document header references 'Medicare Advantage Part B Medical Drugs Step Therapy' indicating a step‑therapy program governs Part B medical drugs for Medicare Advantage members; detailed operational rules are located in the policy but are not fully reproduced in this excerpt.

    Documentation Required

    Document prior use, intolerance, indication gaps or 365‑day continuation for non‑preferred coverage

    To support coverage of a non‑preferred product, providers must document history of prior use of preferred products, documented intolerances/contraindications/adverse events to preferred products, lack of FDA indication for the preferred product, or evidence of continuation of prior therapy within the past 365 days.

    • Include clinical notes documenting trials and responses to all preferred agents.
    • Document adverse events or contraindications to preferred agents.
    • Provide dates or paid claim evidence showing therapy continuation within 365 days.
    Documentation Required

    Expect to provide clinical documentation with PA requests

    A general documentation header is present in the policy; providers should expect to supply clinical documentation when requesting exceptions or prior authorization, though detailed submission forms/processes are not included in this excerpt.

    Documentation Required

    Provide treprostinil NDC(s) when requested

    National Drug Codes for treprostinil formulations are listed in the codes appendix; when required by the payer, providers should supply the exact NDC on the claim or authorization request to reflect preferred versus non‑preferred status.

    • Preferred treprostinil NDC examples: 00781‑3420‑80, 00781‑3425‑80, 00781‑3427‑80, 00781‑3430‑80.
    Billing Rule

    Include exact NDC or HCPCS when billing treprostinil

    When billing treprostinil or similar agents, include the specific NDC or the listed HCPCS/brand code so the claim matches the payer's preferred/non‑preferred mapping and to support correct adjudication.

    • Example: include J3285 and the exact NDC on the claim to reflect preferred vs non‑preferred status.
    Billing Rule

    Claims must include exact NDC and HCPCS/Q codes from the appendix

    Submit the exact NDC and HCPCS/Q‑code listed in the codes appendix for treprostinil and related agents to ensure the payer can match the product to its preferred/non‑preferred designation.

    • Claims should list the HCPCS J3285 for treprostinil and the precise NDC from the appendix.
    • Mismatched or missing NDC/HCPCS may result in processing delays or non‑preferred handling.
    Billing Rule

    Submit the exact code/NDC that matches the administered product

    Providers must submit the specific HCPCS/HCPCS‑like code or NDC that corresponds to the administered product as listed (for example, J3285 for treprostinil); mismatches can affect coverage classification.

    • Example codes: J3285 (treprostinil), J1745 (infliximab) and applicable Q‑codes for biosimilars.
    Documentation Required

    Use listed treprostinil NDC examples on claims/PA requests

    Examples of treprostinil NDCs are provided in the policy; when required for claims or authorization, include these exact NDC values (e.g., 00781‑3420‑80, 00781‑3425‑80, 00703‑0666‑01) to reflect the product's preferred or non‑preferred status.

    • Examples: 00781‑3420‑80; 00781‑3425‑80; 00703‑0666‑01; 42023‑0206‑01.
    Documentation Required

    Document exact treprostinil/Remodulin NDC on claims

    National Drug Codes for treprostinil and Remodulin are enumerated throughout the code appendix; include the exact NDC on claims to match the policy's preferred/non‑preferred groupings when requesting authorization or billing.

    • Multiple NDCs are grouped as Preferred or Non‑Preferred—select and report the exact NDC used.
    Note

    Use the codes appendix to match product codes and NDCs for PA/claims

    The codes appendix is a detailed coding list that associates drug products, biosimilars, NDCs and HCPCS/Q‑codes; use this appendix entries when preparing authorization requests and claims, recognizing that operational PA text may be located elsewhere in the policy.

    Denial Risk

    Non‑preferred requests may be denied without documented exceptions

    Requests for non‑preferred products may be denied unless the member meets one of the policy's step‑therapy exceptions (failure of all preferred products, contraindication/intolerance to all preferred products, lack of FDA indication for a preferred product, or continuation within 365 days).

    • If exception criteria are not met, the non‑preferred request may be declined.
    Denial Risk

    Administering non‑preferred therapy without PA risks claim denial

    If a provider administers a non‑preferred therapy without obtaining prior authorization, Blue Cross of Idaho may deny claims for the non‑preferred therapy.

    • Obtain preservice prior authorization for non‑preferred medical‑benefit therapies to avoid denial risk.
    Denial Risk

    Coding mismatches (HCPCS/Q) can trigger denials or special handling

    Claims may be denied or require special handling if submitted with incorrect HCPCS/Q‑codes or if biosimilar versus reference‑product coding is inconsistent with the payer's listings; ensure coding matches the policy appendix entries.

    • Check that biosimilar Q‑codes or originator J‑codes used on claims match the product actually administered.
    Denial Risk

    Non‑Preferred NDCs can trigger coverage restrictions

    Use of non‑preferred NDCs or product presentations listed as Non‑Preferred may trigger coverage restrictions or require prior authorization per the code appendix.

    • Non‑Preferred NDC examples include 66302‑0101‑01, 66302‑0102‑01, 66302‑0105‑01, 66302‑0110‑01.
    Denial Risk

    Non‑preferred NDCs/presentations increase denial risk

    Use of non‑preferred NDCs or non‑preferred product presentations (for example certain treprostinil NDC groups) may be designated Non‑Preferred and could lead to coverage restriction or denial if exception criteria are not documented.

    Denial Risk

    Mismatch between submitted code/NDC and payer mapping may cause denial

    Claims may be denied or require different processing if the submitted NDC or HCPCS code does not match the payer's preferred/non‑preferred mapping for the product (for example, treprostinil NDC groupings).

    Denial Risk

    Non‑Preferred products may be denied without documented exceptions

    Use of products listed as Non‑Preferred (for example certain treprostinil NDC packs flagged Non‑Preferred) may trigger coverage restrictions or denial depending on formulary status and lack of documented exceptions.

    Denial Risk

    Specific listed non‑preferred codes will receive non‑preferred handling

    Use of non‑preferred NDCs/HCPCS (for example the listed non‑preferred codes such as 66302‑0101‑01, 66302‑0102‑01, 66302‑0105‑01, 66302‑0110‑01) may result in non‑preferred coverage handling.

    Note

    Codes appendix shows lists and history; use payer PA process for submissions

    This coding appendix excerpt includes codes and policy history but does not enumerate the specific operational prior authorization forms or exact submission steps; follow payer prior authorization processes and use the code appendix to match submitted codes.

    Note
    Note

    Step Therapy Requirements

    StepRequirement / Exception
    1Demonstrate failure or intolerance to all preferred products, or meet one of the listed exceptions: (a) history of minimal clinical response to ALL preferred products; (b) contraindication/intolerance/adverse event(s) to ALL preferred products; (c) preferred product lacks FDA‑approved indication for the requested use; (d) continuation of prior therapy within the past 365 days.
    StepRequirement
    1Must try ALL preferred products before coverage of a non‑preferred product unless one of the exception criteria is met (minimal response to all preferred products; contraindication/intolerance/adverse events to all preferred products; preferred product lacks FDA‑approved indication; or continuation of prior therapy within 365 days).
    ObservationDetail
    Preferred / Non‑Preferred listings notedPreferred vs non‑preferred designations are shown for treprostinil and other products in the code lists; these listings imply preference or step requirements though explicit step sequences are not provided in this section.
    Listing typeImplication
    Originator and biosimilar entries (infliximab, trastuzumab, pegfilgrastim, etc.)The appendix lists originator biologics alongside biosimilars with 'Preferred' or 'Non‑Preferred' annotations (and some 'excludes biosimilar' notes), indicating product‑level preference that may drive step or substitution policies.
    NDC groupingsPolicy note
    Treprostinil Preferred vs Non‑Preferred NDCsMultiple treprostinil NDCs are labeled Preferred (e.g., 00781‑3420‑80, 00781‑3425‑80, 00781‑3427‑80, 00781‑3430‑80) while other NDCs (e.g., 66302‑0101‑01 series) are listed as Non‑Preferred, suggesting dispensing preference for certain NDCs prior to others.
    Separation of productsEffect on utilization management
    Originator biologics vs biosimilars separated in listsSome originator products are marked 'excludes biosimilar' or explicitly Non‑Preferred; these distinctions may trigger step therapy, substitution, or special prior authorization handling.
    Preferred vs Non‑PreferredOperational expectation
    Preferred product designations presentPreferred product listings (including preferred NDC groups and HCPCS/Q‑codes) suggest plan-level expectation to use preferred codes/NDCs when available for coverage and adjudication.
    Preference designationUtilization impact
    Products flagged Preferred or Non‑Preferred (e.g., treprostinil, infliximab)These preference designations may be enforced via step therapy edits or prior authorization requirements to favor preferred products before approving non‑preferred alternatives.
    Preferred codesExpectation before non‑preferred approval
    Preferred NDCs / HCPCS listed (examples: treprostinil NDCs; J3285)Use of listed preferred NDCs or HCPCS/Q‑codes is expected prior to approving non‑preferred codes; claims should include the exact NDC or HCPCS code to match preference status.
    Header / ProgramContent note
    Medicare Advantage Part B Medical Drugs Step TherapyThe document header indicates a 'Medicare Advantage Part B Medical Drugs Step Therapy' program; however, detailed step therapy sequences beyond the stated exceptions are not provided in the excerpt.

    Continuation of Prior Therapy

    Continuation of Prior Therapy

    Continuation of prior therapy within the last 365 days allows coverage of previously used (including non-preferred) products.

    Continuation of prior therapy: Member has been on the requested therapy (paid claim) within the past 365 days.365 days

    A paid claim within the past 365 days defines 'current drug/product' and qualifies for continuation without requiring switching to a preferred product.

    Continuation of prior therapy

    Continuation of prior therapy

    Look‑back period for continuation: Continuation of prior therapy within the past 365 days qualifies the member for coverage of the previously used product.365 days

    Policy defines 'current drug/product' as a paid claim within the past 365 days; new members or ongoing users are not required to switch products due to formulary changes.

    Initial Therapy Criteria

    Dose/product listing

    Dose listing: Pegfilgrastim products listed at 0.5 mg and eflapegrastim at 0.1 mg.pegfilgrastim 0.5 mg; eflapegrastim 0.1 mg

    Dose/concentration references appear in the product code listings.

    Quantity Limits

    inv-140: Representative agents subject to quantity limits — bevacizumab, denosumab, pegfilgrastim, etc.
    Representative agents subject to quantity limitsBevacizumab, Denosumab, Pegfilgrastim (and biosimilars), Treprostinil, Eflapegrastim
    Other examplesInfliximab group, Trastuzumab and biosimilars, Rituximab group
    ContextQuantity limits referenced in policy's coding and quantity limits sections; specific per-period limits not always stated in excerpt
    inv-141: treprostinil — NDC-specific (preferred vs non-preferred listed).
    Treprostinil preferenceTreprostinil NDC listings include Preferred vs Non-Preferred NDC groupings (NDC-specific designations)
    NDC examplesPreferred NDCs include 00781-3420-80, 00781-3425-80, 00781-3427-80, 00781-3430-80; additional Remodulin NDCs listed (00703-0666-01 etc.)
    Billing implicationProviders should submit exact NDC to reflect Preferred vs Non-Preferred status on claims
    inv-142: treprostinil — NDC pack lists provided; preference flagged but no explicit quantity-per-period stated.
    NDC pack lists providedMultiple treprostinil NDC pack groups are enumerated (Preferred and additional Remodulin NDCs) in the code appendix
    Preference flaggingPreferred NDCs are explicitly labeled 'Preferred' while other NDCs/series (e.g., 66302-... series) are marked Non-Preferred in listings
    Quantity-per-periodNo explicit quantity-per-period is stated for treprostinil NDC packs in the provided excerpt

    Site of Care

    Note
    Note
    Note
    Note
    Note

    Biosimilar Listings and Handling

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background

    Background: This policy enumerates preferred biologic and specialty medical drugs covered under Blue Cross of Idaho Medicare Advantage Part B. Coverage decisions are mapped to the listed HCPCS/Q-codes and NDCs and defer to FDA‑approved indications and CMS guidance; continuation-of-therapy and documented failures/intolerances to preferred products are key exceptions for non-preferred coverage.

    Definitions

    inv-115: Preferred product — A drug listed by the plan as preferred within a drug class.
    Preferred productA drug listed by the plan as preferred within a drug class; considered medically necessary for FDA/CMS-accepted indications unless an exception applies
    Non-preferred productA drug not listed as preferred; coverage requires meeting one of the specified step-therapy exception criteria
    HCPCS Q-code definitionHCPCS Q-codes identify biosimilar or formulation variants (examples listed alongside reference J-codes)
    inv-116: Non-preferred product — A drug not listed as preferred; coverage requires meeting one of the specified step-therapy exception criteria.
    Non-preferred productA drug not listed as preferred; coverage requires meeting one of the specified step-therapy exception criteria (history of failure/intolerance to all preferred products, lack of FDA indication, or continuation within 365 days)
    Denial riskRequests for non-preferred products may be denied unless an exception is met (per step therapy criteria)
    Provider actionDocument prior use, intolerances, contraindications or continuation within 365 days to support exception request
    inv-117: NCD — National Coverage Determination definition.
    NCD definitionNational Coverage Determination; a CMS decision that an item or service is reasonable and necessary for diagnosis or treatment and within the Medicare benefit category
    RolePolicy defers to NCDs for clinical appropriateness where applicable
    ReferenceDefined in the policy 'DEFINITIONS' section
    inv-118: MAC — Medicare Administrative Contractor definition.
    MAC definitionMedicare Administrative Contractor; private insurer awarded jurisdiction to process Medicare Part A and B medical claims or DME claims
    ExampleNoridian is the A/B MAC for Idaho (Jurisdiction JF) referenced in the policy)
    UseMAC/LCD guidance may inform coverage/coding decisions
    inv-119: LCD / LCA — Local Coverage Determination or Article definition.
    LCD / LCA definitionLocal Coverage Determination or Local Coverage Article: carrier determinations or coding/guidance related to Medicare coverage/coding
    RoleLCDs/LCAs complement NCDs and may guide local coverage/coding
    Reference contextDefined in the policy 'DEFINITIONS' section
    inv-120: HCPCS Q-code — A HCPCS code that may identify biosimilar or specific formulation variants.
    HCPCS Q-codeA HCPCS code that may identify a biosimilar or specific formulation variant (e.g., multiple Q-codes listed adjacent to bevacizumab J9035)
    ExampleQ5107, Q5118, Q5126, Q5129, Q5160 listed for bevacizumab biosimilars (10 mg)
    UseQ-codes are used in the code appendix to differentiate biosimilars from reference products for adjudication
    inv-121: NDC — National Drug Code values provided for treprostinil formulations to identify specific marketed product packages.
    NDCNational Drug Code values provided for treprostinil formulations to identify specific marketed product packages (examples listed)
    Examples00781-3420-80, 00781-3425-80, 00781-3427-80, 00781-3430-80; Remodulin NDCs 00703-0666-01, 00703-0676-01, etc.
    Billing noteProviders should supply exact NDCs when required for claims or benefit determination
    inv-122: Preferred NDC group — An identified set of National Drug Codes labeled 'Preferred' in the code listings.
    Preferred NDC groupAn identified set of National Drug Codes labeled 'Preferred' in treprostinil code listings (e.g., 00781-3420-80, 00781-3425-80, 00781-3427-80, 00781-3430-80)
    PurposeUsed to indicate plan product preference and influence adjudication/step edits
    Provider actionSubmit exact NDC to reflect Preferred group on claims
    inv-123: Biosimilar — A referenced biosimilar product for an originator biologic (e.g., infliximab-dyyb Inflectra).
    Biosimilar exampleInfliximab-dyyb (Inflectra) listed as a biosimilar to infliximab
    ContextBiosimilar Q-codes (e.g., Q5103) appear alongside originator J1745 to permit biosimilar identification
    Policy implicationBiosimilars are enumerated for adjudication and preference may differ between originator and biosimilar
    inv-124: Biosimilar — A biologic product approved as biosimilar to a reference biologic; document lists biosimilar HCPCS/Q-codes separately from originator product codes.
    Biosimilar definitionA biologic product approved as biosimilar to a reference biologic; the document lists biosimilar HCPCS/Q-codes separately from originator products
    ExamplesQ5103 (Inflectra), Q5104 (Renflexis), Q5121 (AVSOLA) listed alongside J1745
    UseSeparate Q-codes enable payer to track biosimilar vs originator utilization
    inv-125: Biosimilar — A biologic product highly similar to an FDA‑approved reference biologic, listed here with distinct Q-codes.
    Biosimilar characterizationA biologic product highly similar to an FDA‑approved reference biologic, listed with distinct Q-codes (trastuzumab and infliximab examples)
    Trastuzumab examplesMultiple trastuzumab biosimilars listed with 10 mg presentations (Ontruzant, Herzuma, Ogivri, Trazimera, Kanjinti, Hercessi)
    Coding implicationDistinct Q/J-codes are used to identify biosimilar products for coverage and billing
    inv-126: Biosimilar — A biologic product approved as a biosimilar (e.g., infliximab-dyyb/Inflectra) listed alongside originator products.
    Biosimilar listing with examplesInfliximab biosimilars (Inflectra Q5103, Renflexis Q5104, AVSOLA Q5121) are listed alongside originator infliximab (J1745); payer distinguishes biosimilar vs originator codes
    Policy handlingOriginator products sometimes annotated as 'excludes biosimilar' or marked Non-Preferred, indicating differentiated treatment
    Operational noteUse correct Q/J-code to reflect biosimilar vs originator on claims to align with payer preference

    Revision History

    2026-04-01policy_effective_dateLatest

    Policy effective date updated to 04/01/2026; coding updates (Q5161 and Q5162) referenced as effective 4/1/26 in the coding appendix.

    2025-12-19policy_revision

    Policy replaced with changes to infliximab and treprostinil products; Blue Cross of Idaho adopted changes effective 01/01/2025 (entry recorded 12/19/24).

    2025-06-26policy_revision

    Policy replaced to add intravitreal vascular endothelial growth factor inhibitors and degeneration categories with applicable codes; adopted changes effective 10/01/2025 (entry recorded 06/26/25).

    2025-03-27policy_revision

    Policy replaced to add new non-preferred trastuzumab product Hercessi; adopted changes effective 07/01/2025 (entry recorded 03/27/25).

    2024-12-19policy_revision

    Policy replaced (12/19/24 entry) with updates to infliximab and treprostinil products; Blue Cross of Idaho adopted changes effective 01/01/2025.

    2024-09-26policy_revision

    Policy replaced (09/26/24 entry) to adopt therapy Ryzneuta and other updates; adopted changes effective 01/01/2025.

    2024-04-25policy_revision

    April 25, 2024 replacement updated the prescription drug section, added non-preferred toxin code for Daxxify, included a table of FDA-approved indications for toxins, clarified trastuzumab statements, and other coding/category updates effective 11/01/2024 or 08/01/2024 as noted.

    2023-09-28policy_creation

    New policy created and added to prescription drug section; adopted effective 01/01/2024 (recorded 09/28/23).